We have extensive experience with over 200 human and non-human cell lines including the NCI-60 panel evaluating drug activity and selectivity using quantitative cell-based assays measuring cell viability, proliferation, drug uptake, and biomarker expression and activation including:
- Lead candidate identification and optimization
- IC50 determinations
- Combination and sequence dosing and analysis
- Effects of agents on cell cycle and apoptosis
- Enzyme and receptor binding assays
- Signal transduction and mechanism of action studies
Contact
Francis Nieves, B.S.
Manager of Preclinical Operations
Phone: (210) 593-5297
Fax: (210) 593-0795
E-mail: francis.nieves@start.stoh.com